Sawai Group Holdings
4887.TTSE PRIMEPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | ¥21.9bn | ¥18.1bn | ¥15.4bn | ¥9.1bn | ¥2.2bn |
| Operating income | ¥18.7bn | ¥14.8bn | ¥12.6bn | ¥6.9bn | −¥106m |
| Ordinary income | ¥18.8bn | ¥14.4bn | ¥12.5bn | ¥6.9bn | −¥230m |
| Total assets | ¥266.0bn | ¥233.6bn | ¥224.0bn | ¥188.3bn | ¥192.0bn |
| Net assets / equity | ¥171.3bn | ¥162.5bn | ¥190.2bn | ¥178.0bn | ¥176.6bn |
| EPS (basic) | ¥128.74 | ¥90.97 | ¥137.34r | ¥52.88r | ¥-230.38r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 213 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 186 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 82 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 159 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 118 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 88 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 135 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 118 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 118 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 88 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 68 figures · EDINET |
3 more reports are still being processed.
Segments · FY ended 2023-03
| Segment | External sales | Profit |
|---|---|---|
| Japan | ¥163.7bn | ¥16.1bn |
| USA | ¥36.6bn | ¥930m |
| Adjustments & eliminations | — | ¥0 |
| Total | ¥200.3bn | ¥17.0bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.